(RTTNews) – BioXcel Therapeutics Inc. (BTAI) announced the completion of the final patient visit in its pivotal Phase 3 SERENITY At-Home clinical trial, marking a significant milestone in the development of IGALMI (dexmedetomidine) for outpatient use.